VCYT News and Press, Veracyte Inc. From 03/17/23

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...

Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-...

Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022, the company had $178.9 million in cash, cash equivalents and short-term investments. The...

2023-03-10 09:30:00 ET Rising interest rates and fears of a recession have caused a great deal of uncertainty over the past 12 months. This explains why the Nasdaq Composite has dipped 13% during that time. But there are plenty of growth-oriented companies whose stocks have outperfo...

Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences. Cowen’s 43rd Annual Health Care Conference – Boston, MA Presentation on Marc...

The following slide deck was published by Veracyte, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Veracyte, Inc. 2022 Q4 - Results - Earnings Call Presentation

Start Time: 16:30 End Time: 17:29 Veracyte, Inc. (VCYT) Q4 2022 Earnings Conference Call February 22, 2023, 16:30 PM ET Company Participants Marc Stapley - CEO Rebecca Chambers - EVP and CFO Tina Nova - President, U.S. CLIA Business Shayla Gorman - Director...

Veracyte press release ( NASDAQ: VCYT ): Q4 GAAP EPS of -$0.05 beats by $0.09 . Revenue of $80.3M (+19.3% Y/Y) beats by $5.38M . Initiating 2023 annual total revenue guidance of $325 million to $335 million. The consensus estimate is $329.58M. For further det...

Grew Fourth Quarter Revenue to $80.3 Million Grew 2022 Total Revenue to $296.5 Million Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2022. ...

Veracyte ( NASDAQ: VCYT ) is scheduled to announce Q4 earnings results on Wednesday, February 22nd, after market close. The consensus EPS Estimate is -$0.08 (+46.7% Y/Y) and the consensus Revenue Estimate is $74.92M (+11.3% Y/Y). Over the last 1 year, VCYT has beaten EPS est...